

AMENDMENTS TO THE SPECIFICATION

Please replace paragraph 0039 with the following replacement paragraph:

[0039] According to one embodiment, the tartrate salt of the compound, N-(1-methylpiperidin-4-yl)-N-(4-flouorophenylmethyl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide is a potent, selective, orally bioavailable 5-HT_{2A} receptor inverse agonist. One embodiment includes the hydrochloride salt of N-(1-methylpiperidin-4-yl)-N-(4-flouorophenylmethyl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide. The compound of formula (I) also possesses lesser potency as a 5-HT_{2C} receptor inverse agonist and lacks intrinsic activity at the remaining monoaminergic receptor subtypes. Perhaps most notably, the compound of formula (I) lacks activity at dopamine receptor subtypes. (See US Patent Application No. 09/800,096, which is hereby incorporated by reference in its entirety). Extensive behavioral pharmacological profiling of the compound of formula (I), including pre-clinical models of antipsychotic and anti-dyskinetic drug actions, support the therapeutic use of the compound in Parkinson's Disease and related human neurodegenerative diseases.